Winton Group LTD Crispr Therapeutics Ag Transaction History

Winton Group LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$43.23 - $73.83 $236,381 - $403,702	-5,468 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$53.19 - $79.24 $101,699 - $151,506	-1,912 Reduced 25.91%	5,468 $343,000
Q4 2021 Feb 10, 2022	SELL	$70.09 - $111.29 $61,258 - $97,267	-874 Reduced 10.59%	7,380 $559,000
Q3 2021 Oct 28, 2021	BUY	$110.2 - $156.64 $909,590 - $1.29 Million	8,254 New	8,254 $924,000
Q1 2021 Jul 21, 2021	SELL	$110.72 - $210.04 $638,854 - $1.21 Million	-5,770 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$79.67 - $173.23 $1.25 Million - $2.72 Million	-15,702 Reduced 73.13%	5,770 $883,000
Q3 2020 Oct 30, 2020	SELL	$78.5 - $100.64 $2.45 Million - $3.14 Million	-31,190 Reduced 59.23%	21,472 $1.8 Million
Q2 2020 Aug 05, 2020	SELL	$38.5 - $76.05 $1.17 Million - $2.31 Million	-30,330 Reduced 36.55%	52,662 $3.87 Million
Q1 2020 May 11, 2020	BUY	$33.68 - $62.53 $1.03 Million - $1.91 Million	30,477 Added 58.03%	82,992 $3.52 Million
Q4 2019 Feb 13, 2020	BUY	$36.68 - $73.13 $1.93 Million - $3.84 Million	52,515 New	52,515 $3.2 Million

490

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.07B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.